All In Biotech

Drug Trial Radar · NCT06888492

To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)

An Open-label, Dose-escalation Study to Evaluate the Safety and Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)

Last checked: Nov 19, 2026Latest source record: Mar 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

8

Planned (sponsor's estimate)

Start

Mar 28, 2025

Primary completion

Apr 25, 2026

Study completion Apr 30, 2026

Sponsor

Lead sponsor
Guangzhou Jiayin Biotech LtdIndustry
Sponsor type
Industry
First posted
Mar 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of intravitreal injection of EXG202 in subjects with neovascular age-related Macular Degeneration (nAMD).

Conditions

  • Wet Age-related Macular Degeneration (wAMD)
  • Wet Age-related Macular Degeneration

Interventions

  • EXG202Biological

    EXG202 is a gene therapy product for the treatment of wet (neovascular) age-related macular degeneration(wAMD) with a single intravitreal injection and administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability after EXG202 injectionTime frame: up to 52 weeks after treatment

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hebei Eye Hospital

    Xingtai, Hebei, China

  • The Fourth Affiliated Hospital of Zhejiang University School of Medicine

    Yiwu, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.